Indefinite Delivery Contract SPE2DR25D3026

The Indefinite Delivery Contract (IDC) SPE2DR25D3026, awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, is a $9.99 billion single-award contract to provide a comprehensive range of pharmaceutical products and medical supplies in support of military healthcare programs globally. The contract encompasses a 30-month base period with three 30-month option periods, running through December 2036. As the prime vendor, Amerisourcebergen will be responsible for furnishing brand-name, generic, and specialty medications, as well as medical devices, syringes, vaccines, and other critical medical commodities across multiple therapeutic areas. This IDC serves as the primary vehicle for DLA Troop Support to obtain pharmaceutical and medical support for the Department of Defense, U.S. Coast Guard, and other designated government agencies and healthcare programs. The contract was competitively awarded without any set-aside requirements, demonstrating Amerisourcebergen's qualifications and capabilities to meet the government's comprehensive pharmaceutical and medical supply needs worldwide.

The IDC was derived from a broader $30.3 billion solicitation issued by DLA Troop Support to establish the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) contracts. The intent is to have at least three different contractors awarded across the North/EUCOM, West/PACOM, South/SOUTHCOM, and Fleet regions, ensuring resiliency and access to vital pharmaceuticals during contingencies or natural disasters. Both primary and backup suppliers will provide separate distribution fees for brand/generic and specialty pharmaceuticals to support normal and contingency operations globally. The contract will be awarded on a Lowest Price Technically Acceptable (LPTA) basis, with the option to use a reverse auction to obtain the best possible distribution fees.